PHC Corporation Biomedical Division, a subsidiary of healthcare company PHC Holdings Corporation (TOKYO:6523), announced on Wednesday that it has introduced the LiCellMo live cell metabolic analyzer, designed for real-time visualization of cellular metabolism in cell and gene therapy (CGT) research. Leveraging proprietary In-Line monitoring technology, LiCellMo enables continuous measurement of cellular metabolites without disrupting the culture, addressing the need for precise metabolic analysis crucial for developing CGT products, including CAR-T therapies.
LiCellMo's capabilities are essential as the CGT sector accelerates, particularly in areas like cancer immunology and stem cell research. Traditional methods often involve repeated sampling, risking contamination and inconsistent results. LiCellMo mitigates these issues by providing uninterrupted metabolic data, allowing researchers to track cellular changes in real-time, thus facilitating more accurate process development.
Set for launch in Japan this September, followed by select international markets in October, LiCellMo integrates easily into existing lab setups, requiring only PHC's proprietary sensor module. The device supports standard cell culture environments, enabling continuous analysis of glycolysis by monitoring glucose and lactate levels. These features are expected to enhance research outcomes and contribute to the advancement of novel therapies.
PHC Corporation has conducted beta tests of LiCellMo at various research institutions and pharmaceutical companies since 2023. Feedback from these trials highlights the analyzer's ability to provide detailed insights into cellular metabolism, which were previously unattainable with conventional methods.
Breg names new chief executive officer and chief financial officer
Magellan Health launches Teen Mental Wellbeing app powered by BeMe
Azenta names new president and CEO
PHC announces launch of LiCellMo live cell metabolic analyzer targeting CGT advancements
Heron Therapeutics names new chief business officer
Expanse Medical names new chief executive officer and FlowPhysix board member
ClariMed opens new Leeds, UK office
Nightingale Health gains UKCA certification and expands with new laboratory
Talphera enrols first subject in NEPHRO CRRT study
China Pharma Holdings anticipates launch of Dry Eye Disease Therapeutic Device in early 2025
SOPHiA DDM Platform achieves IVDR certification, enhancing diagnostic precision
Medtronic reports FDA approval of Simplera CGM; partners with Abbott